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Introduction
Neoadjuvant chemotherapy (NAC) is currently among 
the mainstem of the treatment of locally advanced breast 
cancer, with the purpose to achieve tumor volume reduction 
and allowing conservative breast surgery (1,2). Overall, 
disease- and lesion-tailored therapeutic strategies are 
increasingly diffused in oncological practice since they tend 
to determine better rates of pathological complete response 
(pCR) after NAC (3). As well, pCR is an accepted predictor 
of better disease-free and overall survival rates (4). On the 
other hand, the effectiveness of NAC increases the number 
of patients receiving surgery with smaller residual tumors; 
this represents a diagnostic challenge for the radiologist.
An association has been traditionally demonstrated 
between tumor histology (i.e., ductal invasive vs. lobular 
invasive), responsiveness to therapy and late survival. 
More recently, the role of lesion phenotype has gained 
increased attention, in predicting biological behavior. 
In particular, analyzed patterns include the presence of 
hormone receptors (HRs) such as: HR+/human epidermal 
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growth factor-2 (HER2)− (so-called luminal tumors); 
the HR−/HER2+ (so-called HER2 positive tumors); the 
HR−/HER2− (so-called triple-negative tumors); the HR+/
HER2+ lesions (so-called hybrid tumors).
Magnetic resonance imaging (MRI) plays an important 
role in the assessment of response to NAC and, therefore, 
to tailor the subsequent management strategy. A large 
dedicated meta-analysis of 2,050 patients from 44 studies 
underlined that MRI has good accuracy for the detection 
of pCR after NAC [area under the curve (AUC) =0.88], 
greater than the accuracy of mammography (P=0.02) 
and that of clinical examination alone. Nevertheless, the 
accuracy of tumor phenotype in predicting pCR has been 
poorly assessed (5). In a previous work conducted on a 
monocentric series of 225 patients, we suggested that tumor 
phenotype evidenced through breast biopsy influences the 
diagnostic performance of MRI: in particular, the triple 
negative and HER2+ subgroups showed adequate receiver 
operating characteristic curve (ROC) AUCs for detection 
of pCR (0.766 and 0.813, respectively) as opposed to the 
luminal and hybrid tumors (0.588 and 0.567, respectively) 
(6,7). To this subject, Lindberg and coworkers recently 
published a literature review of 15 investigations published 
in the 2010–2014 period; they concluded for too weak 
evidence to definitely support the idea of differential MRI 
diagnostic capabilities according to tumor subtypes (8). 
Nonetheless, the time span of papers included suggests the 
need of an updated review of the evidence on this subject.
The results of pathology may be integrated by 
radiological parameters such as the value of the apparent 
diffusion coefficient (ADC). One review questioned 
the value of pre-treatment ADC for the discrimination 
between responders and non-responders (9). This review 
was nonetheless based on underpowered investigations 
and, more importantly, it did not take into consideration 
stratification by phenotypes. We previously confirmed this 
concept in the overall population of patients with locally 
advanced breast cancer, but at the same time suggested that 
the triple-negative and HER2+ tumors are characterized 
by ameliorated diagnostic performance through ADC 
calculation (7).
Our purpose is to revise current literature about the 
relationship between tumor subtypes and diagnostic 
performance of MRI monitoring tumor response to NAC. 
We also discuss the potential role of ADC measurement in 
assessing tumor response. Data are expected to be of help in 
the decision-making process for the increasing number of 
patients undergoing NAC for breast cancer.
Methods
In July 2017, we conducted a literature search in the 
PubMed National Center for Biotechnology Information, 
National Institutes of Health database (MEDLINE). The 
search was limited to abstracts published between January 
2000 and June 2017. The abstracts had to be written in 
English, and the keywords entered for searching under the 
categories “search word” and “subject heading” included: 
neoadjuvant chemotherapy; breast cancer; MRI; breast 
tumor phenotypes; complete response; apparent diffusion 
coefficient; diffusion-weighted imaging (DWI). Data that 
have not undergone peer review and proprietary studies 
were excluded. Studies had to include data about diagnostic 
performance of MRI for either the pre-treatment prediction 
of pCR to NAC, or the detection of pCR. Although the focus 
of the review concerns the impact of tumor phenotypes on 
the diagnostic performance of phenotypes, studies involving 
no stratification according to phenotypes were also noted 
and discussed. We included investigations with variable 
definitions of complete response as the outcome variable, 
since our purpose was to address the impact of tumor 
phenotype on MRI diagnostic performance. To the purposes 
of the present investigation, ‘MRI’ or ‘MRI examination’ 
identifies the MRI study performed after the conclusion of 
NAC, otherwise differently indicated.
Rationale for investigation of tumor phenotypes 
in MRI
A large body of literature exists on the accuracy and 
diagnostic performance indexes for MRI in the prediction 
of pCR, based on morphological factors [i.e., RECIST 
classification (10)]. In a cumulative evaluation of the evidence, 
the accuracy of MRI in this context is reported to be 0.88 (5). 
Beyond imaging-based elements, the same systematic review 
indicated significantly variable relative diagnostic odds ratios 
(RDORs) for MRI depending on several factors, some of 
which are available at the time of MRI examination (such 
as patient’s age (RDOR =0.58 for patients aged >50), tumor 
stage [RDOR =0.79 for stage I or II), type of chemotherapy 
protocol (RDOR =2.02 for anthracycline + taxane protocols), 
time between therapy and MRI (RDOR =0.99 for one-day 
increase), biological features of the disease such as histology 
(RDOR =0.97 for 10% increase in IDC) and phenotype 
(RDOR =1.13 for HER2 expression >30% and RDOR =1.21 
for each 10% increase in ER expression)]. Conversely, other 
factors are not available at the moment of MRI (presence vs. 
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absence of in situ disease, scattered cells within the tumor 
bed). Essentially, it is underlined that a number of factors 
significantly affecting the effectiveness of MRI in identifying 
response to NAC can become available only later, after final 
histopathologic analysis. Performance reduction because 
of false-positive results may be due to inflammatory and 
reactive tissue changes associated with NAC. Although the 
above-referenced meta-analysis represent a reference work 
in the field, it included papers published until 2010, which 
explains its limited capability to clarify issues associated with 
phenotypes.
Differential  behavior associated with opposite 
biological subtypes of breast cancer can probably help in 
the stratification of the likelihood of elements affecting 
the diagnostic performance of MRI: at the current state 
of knowledge, stratification by tumor phenotypes is the 
best available option to achieve such goal. Phenotypes are 
known at the time of post-NAC MRI examination, since 
this information is required to guide NAC regimen and is 
obtained through breast biopsy during the initial diagnostic 
phase. Hence, several studies have addressed the differential 
diagnostic characteristics of MRI depending on phenotypes.
Tumor phenotype and MRI
The evaluation of literature on performance of MRI post- 
according to tumor phenotypes (Table 1) needs to take 
into account variable definitions of pCR. In fact, most 
papers adopt absence of invasive disease in the tumor bed 
as definition of pCR, one adopts absence of both invasive 
and in situ components to define pCR, others require 
also negativity of axillary lymph nodes to define pCR). 
Additionally, diagnostic performance of MRI is in several 
cases presented as Sensitivity/Specificity/Accuracy rates, 
while in others methods based on size concordance between 
MRI and pathology, others report ROC AUC values. 
Despite recognized immunopathological tests (positivity/
negativity of HRs and HER2), various modalities of tumor 
phenotype definition exist (Table 1), ranging between two 
and four classes. Despite these challenges, it is possible 
to enlighten a global concordance between the available 
evidence.
Accuracy for detection of pCR in a non-stratified 
population is globally concordant among papers, ranging 
between 73.1% and 83%. After stratification by phenotypes, 
accuracy (or other measurement of diagnostic performance) 
tend to be better among the TN and in HER2+ tumors not 
expressing HRs (Figures 1,2). McGuire et al. (11) employed a 
two-class stratification (TN and HER2+ vs. all HR+ lesions) 
and observed a marked difference in accuracy (73.6% vs. 
27.3%) in a large single-center series of 203 cases. Of 
note, data in this study were obtained from a prospectively 
collected registry. Such conclusion is also obtained 
from investigations based on rather different methods 
of estimation of response to NAC: the breast response 
index (BRI), initially proposed by Rodenhuis et al. (12) 
and consisting in a score based on several MRI variables 
to describe response, showed an excellent correlation 
within TN and HER2+ tumors, while no significant 
correlation was evidenced for HR-expressing diseases (13). 
The Authors underlined inaccuracy of MRI for ER-
expressing tumors, with the latter as the main biological 
factor associated with decreased performance. The so-
called hybrid subgroup (expressing both HER2 and ER) is 
not reported independently in the study by Loo et al., but, 
interestingly, it shows the worse diagnostic performance for 
MRI among the four phenotype subgroups defined in our 
previous investigation [accuracy =64.3% (7)]. This element, 
beyond the potential consequences for management 
protocols, recalls the close relationship between biological 
behavior and radiological MRI-based diagnostic capabilities 
as the expression of tissue characteristics. Lesser powered 
investigations failed to disclose a significant difference, 
in terms of diagnostic accuracy, between HR+ and HR− 
tumors: nonetheless, in a more detailed analysis they also 
evidenced greater negative predictive value (NPV) among 
HR- tumors (56% vs. 88% in HR− lesions) (14). This 
aspect recurs in other investigations, such as in that by 
De Los Santos et al. (15). In this robust multicentre study 
(746 patients from 8 institutions) the NPV for detection of 
pCR was greatest among TN and HER2+ lesions (60% and 
62%, respectively), i.e., the HR− tumors. Instead, HR+/
HER2+ and HR+/HER2− lesions had their diagnostic 
performance hampered mainly by limited NPV (42% 
and 33%, respectively). It could be surprising to note that 
this very large study fails to identify significantly different 
diagnostic accuracy between HR− and HR+ tumors. Such 
apparent discrepancy can probably be explained by the 
absence of in situ component being used in this study 
as a criterion to define pCR, with consequent increase 
of false negative results with respect to the remaining 
papers in Table 1. This issue will be addressed again 
in the following paragraph about diffusion imaging. 
As well, the latter paper essentially confirms single-
center findings by the same group obtained from a 
smaller cohort (16), although the single-center data 
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Table 1 Overview of studies addressing the impact of tumor phenotypes on the diagnostic performance of MRI in the context of NAC
Study
N of 
patients
Definition of tumor 
response
Rate of tumor 
response
% accuracy of 
MRI (overall)
Phenotype classification
% accuracy of MRI  
(by phenotype*)
Hayashi et al., 
2013
264 Absence of invasive 
disease
37% 73.1 Luminal/HER2− 81.7
Luminal/HER2+ 66.7
Non-luminal/HER2+ 57.6
TN 81.8
Moon et al., 2013 463 Absence of invasive 
disease1
11.4% 0.6642 Luminal A 0.5312
Luminal B 0.5832
HER2+ 0.742
TN 0.7542
De Los Santos  
et al., 2011 
81 Absence of invasive 
disease
39.5% 75.3 HR+/HER2− 75.8
HR+/−/HER2+ 56.5
TN 84
Chen et al., 2011 50 Absence of invasive 
disease
28% 843 HER2+ 883
HER2−/HR+ or HR− 823
De Los Santos  
et al., 2013
746 Absence of both 
invasive disease and 
in situ component
24% 74 HR+/HER2− 80
HR+/HER2+ 70
HR−/HER2+ 69
TN 69
Loo et al., 2011 188 Absence of residual 
disease
20.2% 0.4654 ER+/HER2− 0.0744
HER2+ 0.4264
TN 0.6054
McGuire  
et al., 2011
203 Absence of invasive 
disease
25.1% NA HR+ (luminal A/B) 27.35
HR− (HER2+/TN) 73.65
Fangberget  
et al., 2011
31 Absence of invasive 
disease
35.5% 77 HER2+ 1005
HER2− 505
Kuzucan  
et al., 2012
54 Absence of invasive 
disease
31.5% 83 HR+ 82
HR− 88
Bufi et al., 2015 225 Absence of invasive 
disease
17.3% 79.6 HR+/HER2− 81.1
HR+/HER2+ 64.3
HR−/HER2+ 82.4
TN 83.8
*, referring to phenotype classes in the previous column; 1, includes absence of invasive disease within the axillary lymph nodes; 2, in 
the paper by Moon et al., no accuracy rate is reported; instead, a Pearson correlation is computed between residual tumor size on MRI 
and on pathology; we report the correlation coefficient as a measure of strength of association; 3, in this work, accuracy is given for the 
detection of residual disease instead of pCR; 4, in the paper by Loo et al., the performance of MRI is analyzed through correlation with the 
breast response index (Rodenhuis et al. Ann Oncol 2010); 5, in these papers, accuracy data by phenotype are not available and cannot be 
extrapolated; NPV value by phenotypes is presented instead. MRI, magnetic resonance imaging; NAC, neoadjuvant chemotherapy; NA, 
not available; TN, triple negative; HR, hormone receptor.
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A B
C D
Figure 1 A 45-year-old patient with invasive ductal carcinoma, triple negative phenotype, in lower quadrants of the right breast. (A) Breast 
magnetic resonance imaging axial 3D-FSPGR T1-weighted with fat suppression and contrast media; (B) sagittal 3D-FSPGR T1-weighted 
with fat suppression and contrast media; (C) diffusion Weighted Imaging slice with b =1,000 s/mm2 and; (D) apparent diffusion coefficient 
(ADC) map. The pretreatment ADC value was 1.12×10−2 mm2/s, lower than the cutoff value. 3D-FSPGR, 3-dimensional-fast spoiled 
gradient echo; ADC, apparent diffusion coefficient.
are difficultly comparable to the multicentre database 
due to lack of stratification of HER2+ tumors into 
those expressing or not HRs. As such, it seems that 
s t rat i f icat ion by  HER2+ express ion can provide 
useful insights. Although their study is underpowered 
(31 cases), Fangberget et al. (17) indicates 100% NPV 
among HER2+ lesions vs. 50% in HER2− cases.
Nonetheless, the above study categorized patients 
according to HER2+ positivity only, and both subgroups 
included a proportion of HR-expressing lesions. Such 
consideration might explain the limited difference in 
accuracy between HER2+ vs. HER2− cases (88% vs. 82%) 
in the study by Chen et al. (18). In our opinion, these data 
suggest that HR status also impacts in a non-negligible 
way the performance of MRI: performance is therefore the 
result of the interplay of both HER2 and HR expression. 
In fact, we previously suggested that HR positivity prevails 
over HER2+ positivity in determining worse diagnostic 
performance (ROC AUC reportedly being 0.9 in TN 
lesions, 0.826 in HER2+/HR−, 0.693 in HER2−/HR+, and 
0.611 in HER2+/HR+) (6). Concordantly, Moon et al. (19) 
identify the HR expression status as a major determinant 
of MRI performance. They provide no accuracy rate but 
correlation coefficient of residual tumor size between 
MRI and pathology findings instead. Despite that, 
correlation coefficient was lower and similar for HER2+/
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HR+ and HER−/HR+ (0.531 and 0.583) than for HER2+/
HR− and TN (0.74 and 0.754), suggesting improved 
diagnostic capabilities in the latter two subgroups. Such 
finding is confirmed by multivariate analysis. Only one 
paper suggests lower accuracy in HER2+ tumors than in 
HR+ cases, while confirming greatest accuracy among 
TN lesions (81.8%) (20). They also indicate that better 
performance in the TN subgroup is associated with 
optimized Positive Predictive Value rather than NPV. 
Remarkably, a recent work strongly underlined the 
different behavior among TN and HR−/HER2+ tumors vs. 
HR+ cases, in the term that absence of late enhancement 
in these cases strongly associates with pCR, the AUC of 
MRI in these settings being 0.88 (21).
Potential role of the ADC variation in phenotype 
subgroups
In the previous section, we have addressed the strengths 
and pitfalls of post-NAC MRI in the prediction of 
pCR according to tumor phenotype. Overall, there is 
concordance about the relative diagnostic weakness of MRI 
in the subgroups expressing HRs. Such considerations 
are based on the morphological MRI criteria (RECIST 
classification) (10). It can be hypothesized that additional 
information can be yielded in this specific context through 
the use of DWI and calculation of the ADC. While the 
largest part of the literature focused on the evaluation of 
ADC difference throughout NAC as an additional measure 
to predict response (22-24), only one investigation addressed 
the ADC variation after NAC as a measure of prediction 
of pCR stratified by tumor phenotype (6). Herein, the 
employment of an ADC variation-based method to predict 
pCR was not associated with diagnostic improvement vs. 
the RECIST criteria in the TN and HR-/HER2+ cases 
(ROC AUC =0.8 and 0.833, respectively, vs. 0.9 and 0.826 
for morphological MRI). Conversely, ROC AUCs for the 
ADC variation-based method in the HR+/HER2− (luminal) 
and HR+/HER2+ (so-called hybrid) were 0.787 and 0.722, 
respectively, both reaching statistical significance. In the 
same subgroups, ROC AUCs for the RECIST method were 
0.693 and 0.611, reaching no or little statistical significance. 
This finding suggests a potential for filling this diagnostic 
gap through the coupling of morphological MRI and DWI; 
the radiologist might therefore adapt his/her judgement on 
the basis of the known tumor phenotype. Another group 
proposed the calculation of the ADC ratio (mean post-
treatment ADC/mean pretreatment ADC), which was 
reported to be significantly increased in cases with pCR (21). 
The Authors supported the idea that the combination 
of these criteria (i.e., molecular subtype of the disease, 
morphological  MRI information and ADC rat io) 
yields an optimal diagnostic performance for pCR 
(ROC AUC =0.92).
The information provided by DWI are based on the 
biological structure of the lesion, and under one point of 
view, it represents the closest MRI parameter to pathology- 
derived data. In such perspective, one can speculate that 
DWI might improve the diagnostic performance mainly by 
increased detection of in situ residual disease. In fact, studies 
including the absence of in situ component to define pCR (in 
addition to absence of invasive disease) tend to show better 
A B C
Figure 2 In the same patient we observed a complete disappearance of the lesion after chemotherapy on both axial (A) and sagittal 
(B) 3D-FSPGR T1-weighted with fat suppression and contrast media injection images. No hyperintense lesion was depicted on DWI 
sequence (C). Pathologic examination showed a pathologically complete response after surgery (tumor regression grade 1). 3D-FSPGR, 
3-dimensional-fast spoiled gradient echo; DWI, diffusion-weighted imaging.
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accuracy for morphological MRI in HR+/HER2− vs. HR-/
HER2+ and TN lesions (15). Further investigations are 
required to confirm the potential role of post-NAC ADC 
to improve predictability of pCR in selected phenotype 
subgroups, and whether the residual in situ component after 
NAC behaves differently in terms of reduction of accuracy 
according to phenotypes.
ADC value before NAC and prediction of pCR
It has been already pointed out that the mean ADC value 
measured before NAC significantly varies according to 
phenotypes; in particular, it is greater among the HR− 
and HR−/HER2+ tumors compared to other subgroups, 
which implies a correlation between such parameter and 
the biological characteristics of individual lesions (25). A 
previous review work concluded for insufficient evidence 
on the effectiveness of pre-NAC ADC in the prediction 
of pCR; yet, such review was limited by the inclusion of 
several underpowered studies and by conflicting definitions 
of response to therapy (9). Li and coworkers defined the 
response to therapy as based on the clinical evaluation 
findings (26) while Park and coworkers based their 
definition of response on the RECIST criteria (27); despite 
these differences, both reported that pre-NAC average 
ADC associated with sensitivity to chemotherapy and to 
the responder status. Another study was concordant (23). 
Yet, they did not perform any analysis by tumor phenotypes. 
Indeed, when the analysis is limited to the overall 
population of breast cancer patients undergoing NAC, 
the majority of the studies are concordant in denying any 
association between pre-treatment ADC and response to 
treatment (7,17,28,29).
On the other hand, when the analysis moves into 
subgroups by phenotypes, a different scenario appears. In 
108 patients, Richard and coworkers evidenced that in TN 
tumors, average pre-treatment ADC value was significantly 
lower in cases who were going to show complete response 
(P=0.047) (29).  Interestingly, in the HR−/HER2+ 
subpopulation, a trend towards lower mean pre-NAC ADC 
was observed; still, significance was not attained (P=0.14) 
probably due to insufficient sample size. Concordantly, no 
meaningful difference emerged in mean ADC for the HR+/
HER2+ and HR+/HER2− subpopulation, which also tended 
to show greater average ADC value among responders. In 
a larger population (N=225) previously analyzed by our 
group (7), we disclosed not only significantly lower mean 
pre-treatment ADC among responders in the TN and 
HR−/HER2+ cohorts, but also adequate and statistically 
meaningful ROC AUCs for the same subgroups (AUC 
=0.766 and P=0.013 for the TN; AUC =0.813 and P=0.03 
for the HR−/HER2+). Inadequate diagnostic performance 
was observed for the HR+/HER2− and HR+/HER2+ cases. 
Again, the biological features of the lesion seem to deeply 
impact the diagnostic performance of MRI.
Conclusions
We have addressed the current literature illustrating the 
impact of tumor phenotype on the diagnostic performance 
of MRI. Given a global concordance of results, we believe 
that the available evidence supports the idea of adapting 
the diagnostic strategy according to tumor phenotype. In 
such perspective, knowledge of phenotype may guide the 
interpretation of imaging and should be declined according 
to the concerned diagnostic step. Specifically, in pre-NAC 
MRI calculation of the ADC value of the lesion may help 
in the prediction of pCR only in the TN and HR-HER2+ 
lesions. In post-NAC MRI, the morphological criteria are 
most accurate in TN and HR−/HER2+ lesions, where ADC 
calculation does not seem to offer a significant advantage. 
On the contrary, in the same post-NAC MRI, the coupling 
of morphological aspects (RECIST) with a criterion 
based on ADC value variation across NAC in the HR+ 
subgroups (i.e., HR+/HER2− and HR+/HER2+), might 
fill the diagnostic gap associated with the use of RECIST 
alone. Generally speaking, the expression of HER2 seem 
to facilitate the diagnostic capabilities of MRI; yet, the 
expression of HRs seems to play a stronger disadvantageous 
effect on accuracy. In fact, the HR+/HER2+ lesions behave, 
with respect to diagnostic performance of MRI, more 
closely to HR+/HER2− lesions than to HR−/HER2+ 
cases. Phenotype-specific interpretation of MRI-derived 
information might represent a further step to personalize 
the knowledge of cancer of individual patients, and to tailor 
the therapeutic management.
In conclusion, the radiologist should keep in mind 
the tumor phenotype at different stages (diagnosis and 
evaluation of response to treatment). Knowledge of disease 
should therefore precede any technological advancement.
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